Boundless Bio, Inc. Overview
Pro stress-test →Boundless Bio is a clinical-stage oncology company developing cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company targets ecDNA, a root cause of oncogene amplification observed in more than 17% of cancer patients.
Strategic Profile
Pro stress-test →The company uses its proprietary Spyglass platform to identify targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
Competitive Landscape
Pro stress-test →Boundless Bio competes in the clinical-stage oncology space against other cancer therapeutics developers. The company's unique focus on ecDNA-targeting represents a differentiated approach compared to conventional checkpoint inhibitors and other cancer therapies in development.
Industry Context
Boundless Bio, Inc. operates in Pharmaceutical/Biotechnology - Clinical-Stage Oncology.
Key facts
Founded: 2018 · Headquarters: San Diego, US · Employees: 64 · Market cap: $24.4M